Hainan Shuangcheng Pharmaceut (002693) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hainan Shuangcheng Pharmaceut (002693) has a cash flow conversion efficiency ratio of 0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥33.67 Million ≈ $4.93 Million USD) by net assets (CN¥404.35 Million ≈ $59.17 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Hainan Shuangcheng Pharmaceut for the company's overall valuation and market capitalisation.
Hainan Shuangcheng Pharmaceut - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Hainan Shuangcheng Pharmaceut's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hainan Shuangcheng Pharmaceut Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hainan Shuangcheng Pharmaceut ranked by their cash flow conversion efficiency. Explore 002693 cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Western Copper and Gold Corp
TO:WRN
|
-0.002x |
|
ASYMCHEM LAB.(TIAN.)H YC1
F:7K90
|
N/A |
|
Concord Securities Co Ltd
TWO:6016
|
-0.162x |
|
Zhejiang Jindao Technology Co. Ltd.
SHE:301279
|
N/A |
|
TomTom NV
AS:TOM2
|
0.065x |
|
Hichain Logistics Co Ltd
SHE:300873
|
0.031x |
|
Propert & Buil
TA:PTBL
|
0.009x |
|
Ichitan Group Public Company Limited
BK:ICHI
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Hainan Shuangcheng Pharmaceut (2009–2025)
The table below shows the annual cash flow conversion efficiency of Hainan Shuangcheng Pharmaceut from 2009 to 2025. View today's stock price for Hainan Shuangcheng Pharmaceut for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥420.53 Million ≈ $61.54 Million |
CN¥60.95 Million ≈ $8.92 Million |
0.145x | +246.12% |
| 2024-12-31 | CN¥411.61 Million ≈ $60.23 Million |
CN¥-40.83 Million ≈ $-5.97 Million |
-0.099x | -541.12% |
| 2023-12-31 | CN¥517.65 Million ≈ $75.75 Million |
CN¥11.64 Million ≈ $1.70 Million |
0.022x | -48.20% |
| 2022-12-31 | CN¥580.94 Million ≈ $85.01 Million |
CN¥25.22 Million ≈ $3.69 Million |
0.043x | +4.45% |
| 2021-12-31 | CN¥566.75 Million ≈ $82.93 Million |
CN¥23.55 Million ≈ $3.45 Million |
0.042x | +336.77% |
| 2020-12-31 | CN¥598.31 Million ≈ $87.55 Million |
CN¥-10.50 Million ≈ $-1.54 Million |
-0.018x | -117.88% |
| 2019-12-31 | CN¥678.26 Million ≈ $99.25 Million |
CN¥66.58 Million ≈ $9.74 Million |
0.098x | +40.36% |
| 2018-12-31 | CN¥669.69 Million ≈ $98.00 Million |
CN¥46.84 Million ≈ $6.85 Million |
0.070x | +336.39% |
| 2017-12-31 | CN¥761.71 Million ≈ $111.46 Million |
CN¥-22.54 Million ≈ $-3.30 Million |
-0.030x | -142.35% |
| 2016-12-31 | CN¥553.13 Million ≈ $80.94 Million |
CN¥38.65 Million ≈ $5.66 Million |
0.070x | +40.17% |
| 2015-12-31 | CN¥927.61 Million ≈ $135.74 Million |
CN¥46.24 Million ≈ $6.77 Million |
0.050x | -12.67% |
| 2014-12-31 | CN¥893.55 Million ≈ $130.75 Million |
CN¥51.00 Million ≈ $7.46 Million |
0.057x | -11.95% |
| 2013-12-31 | CN¥870.62 Million ≈ $127.40 Million |
CN¥56.43 Million ≈ $8.26 Million |
0.065x | -31.65% |
| 2012-12-31 | CN¥845.85 Million ≈ $123.77 Million |
CN¥80.22 Million ≈ $11.74 Million |
0.095x | -67.23% |
| 2011-12-31 | CN¥228.23 Million ≈ $33.40 Million |
CN¥66.05 Million ≈ $9.67 Million |
0.289x | -17.45% |
| 2010-12-31 | CN¥157.82 Million ≈ $23.09 Million |
CN¥55.33 Million ≈ $8.10 Million |
0.351x | -38.27% |
| 2009-12-31 | CN¥77.95 Million ≈ $11.41 Million |
CN¥44.27 Million ≈ $6.48 Million |
0.568x | -- |
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pre… Read more